Indication intelligence, analysis and sector perception

Small rise expected at the open; RegMed sector, jobs report will dictate the day’s movement

March 4, 2016 6:50am

The question is will there be fundamental pressures on which version of sentiment can be sustained?

For your pre-open briefing, subscribe … http://www.regmedinvestors.com/create-account

I say today what others won't, so you can do what others can't; whether information or intelligence is good, bad or somewhere in between – it defines the who, when, where, which and what of it …

U.S. stock futures in a holding pattern ahead of jobs report as investors brace for a much-anticipated jobs report; the open looks set for a small rise at the open, as investors brace for nonfarm payrolls and the market heads for its third straight

European markets traded higher on Friday ahead of the latest nonfarm payrolls data from the U.S.

Asian markets achieved gains for the week despite a tepid session on Friday that saw major indexes waver between positive and negative territory.

Data docket: The new jobs data is released at 8:30 a.m. ET Friday and economists expect 190,000 nonfarm payrolls in February's employment report, and the unemployment rate to stay unchanged at 4.9% according to Thomson Reuters.

The stem, cell and gene therapy RegMed sector closed NEGATIVE on Thursday, POSITIVE on Wednesday and Tuesday, NEGATIVE on Monday and POSITIVE on last Friday.

Past five (5) days (of 43 covered companies):

· Thursday closed NEGATIVE with 23 decliners, 18 advancers and 2 flats;

· Wednesday closed POSITIVE with 6 decliners, 35 advancers and 2 flats;

· Tuesday closed POSITIVE with 14 decliners, 26 advances and 3 flats

· Monday closed NEGATIVE with 24 decliners, 16 advancers and 2 flats;

· Last, Friday closed POSITIVE with 9 decliners, 32 advancers and 2 flats;

The stem, cell and gene therapy regenerative medicine (SCGT&RM) opened down and stayed negative Thursday!

I think there is a whole lot of waiting for the weekend after the negative close post two positive closes following a negative Monday following last Friday’s positive close.

It’s been a week of financial results that didn’t quite ring my bell concerning the prospects for Friday.

Investors need a ho-hum jobs report, strong enough to show the economy isn't toppling over but not strong enough to pressure the Fed to raise rates any time soon.

What also worries me is that Asian markets retreated Friday, breaking their recent winning run despite a weak but, positive finish on Thursday.

You’ve made it to the office, turned on the monitor having just gotten your coffee and it hits you - what could be Thursday’s trades?

Cellectis ADR (CLLS) closed UP +$0.99 to $26.41. After four days of increasing share pricing, $25.42, $25.14 and Monday’s $23.81, speculators will “nibble” the edges of appreciation. The after-market indication is -$1.23 - SELL;

Fate Therapeutics (FATE) closed UP +$0.13 to $1.83. The after-market indication is +$0.05 after its Q4/15 financial results reported a -$7.4 M net loss and -$0.26 per share while posting $1.1 M in revenue – BUY;

Juno Therapeutics (JUNO) closed DOWN -$2.03 to $40.71 and has an after-market indication of -$0.30. It has been a good week post the financial results and feeling overbought – SELL;

Intrexon (XON) closed UP +$0.26 to $37.28 after yesterday’s +$3.29 after being up +$2.78 and then down -$2.81. It’s still about the curse of the upside and traders selling into any strength. Speculators could be “nibbling” the edges of recent appreciation – Maintaining SELL;

Stemline (STML) closed UP +$0.73 to $5.52. Friday is a questionable day for the market, basically a “crap-shoot” – speculators could “nibble’ the edges of appreciation after the week to date of closes $4.79, $4.65 and Monday’s $4.81 post Friday’s $4.62 – SELL;

Opinions expressed are those of the author and are subject to change, and are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.